Clinical trial: Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care (NCT04716985)

Eligibility criteria:
Inclusion Criteria:

          -  Age over 60 years old.

          -  Patient with at least 3 of the symptoms of COVID-19 encountered among the 11 below
             dating from a maximum of 4 days defined below :

               1. Fever > 37.5 C for at least 3 days

               2. Cough

               3. Sore throat/cold

               4. Headache

               5. Anosmia, dysgeusia

               6. Myalgias, arthralgias, bone pain

               7. Respiratory difficulties (feeling dyspnea at rest)

               8. Chest pain (sternal)

               9. Digestive complaints (diarrhea, nausea, vomiting)

              10. Tachycardia (palpitation)

              11. Conjunctivitis (red eyes)

          -  Patient who has taken a naso-pharyngeal sample (antigenic test, RT-PCR, RT-LAMP or
             other samples validated by the upcoming HAS) In the case of a negative test, the
             concept of contage (with a certain or probable COVID patient) dates back less than 10
             days.

          -  No seriousness signs during the consultation and for at least 72 hours.

          -  Patient able to understand the procedure and follow it and have tools for a
             video-consultation.

          -  Affiliation to the social security system.

          -  Voluntary to participate to the study, informed consent form signed after appropriate
             information

        Exclusion Criteria:

          -  The absence of general practitioner.

          -  Any sign of seriousness incompatible with home care.

          -  Severe chronic kidney failure or dialysis (i.e. DFGe <30).

          -  drink cure Contraindication (500 ml/d for 21 days).

          -  Contraindication to any drug in the study, including a known allergy, especially
             magnesium.

          -  Uncontrolled and clinically significant heart disease, whether its origin
             (arrhythmias, angina, uncompensated congestive heart failure).

          -  Subject participating to an other clinical study interventional.

          -  Person deprived of liberty or under legal guardianship.

          -  No one in the same household who participated in this study.

          -  Patient refusing hospitalization.

          -  Persons subject to sections L1121-7 and L1121-8 of the CSP (minor, person deprived of
             liberty by judicial or administrative decision, person subject to a legal protection
             measure) or not able to communicate his consent verbally.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 60 Years old.


Patient description (medical language): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient description (patient's own words): I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Does the patient match the trial criteria? Entailment